deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02955758

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response

Sponsor: Joel Neal

Conditions Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Interventions Pembrolizumab
Updated 20 times since 2017 Last updated: Sep 16, 2024 Started: Oct 31, 2016 Primary completion: Apr 9, 2024 Completion: Apr 9, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02955758, this PHASE2 trial focuses on Metastatic Non-Squamous Non-Small Cell Lung Carcinoma and remains completed. Sponsored by Joel Neal, it has been updated 20 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2018 · 15 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Oct 2020 · 12 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Aug 2023 · 14 months · monthly snapshot~Aug 2023 – ~Feb 2024 · 6 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 21 months · monthly snapshot

Change History

20 versions recorded

  1. Nov 2024 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 15 earlier versions

  1. Jun 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  6. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Oct 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  8. May 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  9. Oct 2018 — May 2019 [monthly]

    Recruiting PHASE2

  10. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  11. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  13. Mar 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Feb 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Joel Neal
  • Merck Sharp & Dohme LLC
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations